4.1 Article

Lipid Mediators in Aspirin - Exacerbated Respiratory Disease

Journal

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2016.06.009

Keywords

AA (arachidonic acid); AERD (aspirin-exacerbated respiratory disease); Asthma; COX (cyclooxygenase); Leukbtriene; 5-LO (5-lipoxygenase); NSAID (nonsteroidal inflammatory drug); Prostaglandin

Ask authors/readers for more resources

Aspirin-exacerbated respiratory disease (AERD) is a syndrome of severe asthma and rhinosinusitis with nasal polyposis with exacerbations of baseline eosinophil-driven and mast cell driven inflammation after nonsteroidal antiinflammatory drug ingestion. Although the underlying pathophysiology is poorly understood, dysregulation of the cyclooxygenase and 5-lipoxygenase pathways of arachidonic acid metabolism is thought to be key. Central features of AERD pathogenesis are overproduction of proinflammatory and bronchoconstrictor cysteinyl leukotrienes and prostaglandin (PG) D-2 and inhibition of bronchoprotective and antiinflammatory PGE(2). Imbalance in the ratio of these lipid mediators likely leads to the increased eosinophilic and mast cell inflammatory responses in the respiratory tract.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available